Vun James, Iqbal Neelam, Jones Elena, Ganguly Payal
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds LS9 7TF, UK.
Leeds Orthopaedic & Trauma Sciences, Leeds General Infirmary, University of Leeds, Leeds LS97TF, UK.
Bioengineering (Basel). 2023 Aug 21;10(8):987. doi: 10.3390/bioengineering10080987.
Aging and age-related changes impact the quality of life (QOL) in elderly with a decline in movement, cognitive abilities and increased vulnerability towards age-related diseases (ARDs). One of the key contributing factors is cellular senescence, which is triggered majorly by DNA damage response (DDR). Accumulated senescent cells (SCs) release senescence-associated secretory phenotype (SASP), which includes pro-inflammatory cytokines, matrix metalloproteinases (MMPs), lipids and chemokines that are detrimental to the surrounding tissues. Chronic low-grade inflammation in the elderly or inflammaging is also associated with cellular senescence and contributes to ARDs. The literature from the last decade has recorded the use of platelet rich plasma (PRP) to combat senescence and inflammation, alleviate pain as an analgesic, promote tissue regeneration and repair via angiogenesis-all of which are essential in anti-aging and tissue regeneration strategies. In the last few decades, platelet-rich plasma (PRP) has been used as an anti-aging treatment option for dermatological applications and with great interest in tissue regeneration for orthopaedic applications, especially in osteoarthritis (OA). In this exploration, we connect the intricate relationship between aging, ARDs, senescence and inflammation and delve into PRP's properties and potential benefits. We conduct a comparative review of the current literature on PRP treatment strategies, paying particular attention to the instances strongly linked to ARDs. Finally, upon careful consideration of this interconnected information in the context of aging, we suggest a prospective role for PRP in developing anti-aging therapeutic strategies.
衰老及与年龄相关的变化会影响老年人的生活质量（QOL），导致其运动能力和认知能力下降，并增加患年龄相关疾病（ARDs）的易感性。其中一个关键因素是细胞衰老，它主要由DNA损伤反应（DDR）触发。积累的衰老细胞（SCs）会释放衰老相关分泌表型（SASP），其中包括对周围组织有害的促炎细胞因子、基质金属蛋白酶（MMPs）、脂质和趋化因子。老年人的慢性低度炎症或炎症衰老也与细胞衰老有关，并会导致ARDs。过去十年的文献记录了富血小板血浆（PRP）用于对抗衰老和炎症、作为镇痛药缓解疼痛、通过血管生成促进组织再生和修复——所有这些在抗衰老和组织再生策略中都至关重要。在过去几十年里，富血小板血浆（PRP）已被用作皮肤科应用的抗衰老治疗选择，并在骨科应用的组织再生方面引起了极大兴趣，尤其是在骨关节炎（OA）方面。在本探索中，我们将衰老、ARDs、衰老和炎症之间的复杂关系联系起来，深入研究PRP的特性和潜在益处。我们对当前关于PRP治疗策略的文献进行了比较性综述，特别关注与ARDs密切相关的实例。最后，在仔细考虑衰老背景下的这些相互关联的信息后，我们提出PRP在制定抗衰老治疗策略方面的潜在作用。
